UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $7.35 Million Stake in Dianthus Therapeutics, Inc. $DNTH

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 24.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 75,396 shares of the company’s stock after purchasing an additional 14,961 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Dianthus Therapeutics were worth $7,350,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. ABS Investment Management LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $194,960,000. PNC Financial Services Group Inc. grew its stake in shares of Dianthus Therapeutics by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after acquiring an additional 139 shares in the last quarter. First Horizon Corp bought a new position in Dianthus Therapeutics during the first quarter worth about $32,000. Virtus Investment Advisers LLC increased its position in Dianthus Therapeutics by 7.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after acquiring an additional 416 shares during the period. Finally, EFG International AG bought a new position in Dianthus Therapeutics during the second quarter worth about $49,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

DNTH stock opened at $108.10 on Tuesday. Dianthus Therapeutics, Inc. has a 52 week low of $24.49 and a 52 week high of $117.88. The business has a 50-day simple moving average of $105.48 and a 200 day simple moving average of $89.79. The company has a market cap of $5.91 billion, a PE ratio of -26.05 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 23,124 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $425,640. The trade was a 85.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Anne McGeorge sold 7,750 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the transaction, the director owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This represents a 86.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 283,678 shares of company stock worth $29,672,400 in the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush raised their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Citigroup started coverage on Dianthus Therapeutics in a research report on Friday. They set a “buy” rating and a $156.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $126.92.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.